Drug Trial Radar · NCT06275763
Optimal Medical Treatment of Difficult-to-treat Hypertension
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,500
Planned (sponsor's estimate)
Start
Oct 20, 2023
Primary completion
Dec 1, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- National Institute of Cardiology, Warsaw, PolandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate best medical management to achieve the BP goals of ESC/ESH (120-129 / 70-79 mmHg) in HT patients who are \<65 years old and ineffectively treated (BP ≥ 130/80 mg) with 3 or more antihypertensive drugs
Conditions
- Hypertension
Interventions
Phase C: EplerenoneDrug
Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
Phase C: SpironolactoneDrug
Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
Phase C: TorasemideDrug
Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
Phase B: Triplixam / Elestar HCTDrug
Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
Phase A: Confirmation of uncontrolled hypertensionDiagnostic test
Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients with uncontrolled BP on ABPMTime frame: First week of the patients' participation in the study
- Patients with controlled BP after 12 weeks on triple SPCTime frame: Next 12 weeks of the patients' participation in the study
- Systolic BP reduction on 4th antihypertensive drugTime frame: Last 24 weeks of the patients' participation in the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Cardiology
Warsaw, Masovian Voivodeship, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.